CERo Therapeutics (CERO)

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.

https://www.cero.bio

• YTD Return

  CERO-97.74%
  S&P 500+24.05%

• 1-Year Return

  CERO-97.72%
  S&P 500+31.08%

• 3-Year Return

  CERO-97.51%
  S&P 500+29.56%

• 5-Year Return

  CERO-97.51%
  S&P 500+29.56%